American Radium Society Appropriate Use Criteria for the use of liver-directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines.
colorectal cancer
liver metastases
liver-directed
local therapies
metastasis-directed therapy
therapy
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 10 2023
15 10 2023
Historique:
revised:
09
05
2023
received:
09
03
2023
accepted:
24
05
2023
medline:
22
9
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
ppublish
Résumé
The liver is a common site of cancer metastases. Systemic therapy is widely accepted as the standard treatment for liver metastases (LM), although select patients with liver oligometastases may be candidates for potentially curative liver resection. Recent data support the role of nonsurgical local therapies such as ablation, external beam radiotherapy, embolization, and hepatic artery infusion therapy for management of LM. Additionally, for patients with advanced, symptomatic LM, local therapies may provide palliative benefit. The American Radium Society gastrointestinal expert panel, including members representing radiation oncology, interventional radiology, surgical oncology, and medical oncology, performed a systemic review and developed Appropriate Use Criteria for the use of nonsurgical local therapies for LM. Preferred Reporting Items for Systematic reviews and Meta-Analyses methodology was used. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in seven representative clinical scenarios through a well-established consensus methodology (modified Delphi). A summary of recommendations is outlined to guide practitioners on the use of nonsurgical local therapies for patients with LM.
Substances chimiques
Radium
W90AYD6R3Q
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3193-3212Informations de copyright
© 2023 American Cancer Society.
Références
Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157-166. doi:10.1016/j.radonc.2020.04.003
Moehler M, Folprecht G, Heinemann V, et al. Survival after secondary liver resection in metastatic colorectal cancer: comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). Int J Cancer. 2022;150(8):1341-1349. doi:10.1002/ijc.33881
Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020;395(10229):1078-1088. doi:10.1016/S0140-6736(20)30164-1
Tan AC, Bagley SJ, Wen PY, et al. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer. 2021;9(7):e002459. doi:10.1136/jitc-2021-002459
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309-318. discussion 318-21. doi:10.1097/00000658-199909000-00004
Yoo TG, Cranshaw I, Broom R, Pandanaboyana S, Bartlett A. Systematic review of early and long-term outcome of liver resection for metastatic breast cancer: is there a survival benefit? Breast. 2017;32:162-172. doi:10.1016/j.breast.2017.02.003
Loupakis F, Sharma S, Derouazi M, et al. Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases. JCO Precis Oncol. 2021(5):1166-1177. doi:10.1200/PO.21.00101
Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14(1):810. doi:10.1186/1471-2407-14-810
Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759-766. doi:10.1097/00000658-200206000-00002
Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie Cancer. 1996;77(7):1254-1262. doi:10.1002/(sici)1097-0142(19960401)77:7<1254::aid-cncr5>3.0.co;2-i
Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575-4580. doi:10.1200/JCO.2007.11.0833
Mohammad WM, Martel G, Mimeault R, Fairfull-Smith RJ, Auer RC, Balaa FK. Evaluating agreement regarding the resectability of colorectal liver metastases: a national case-based survey of hepatic surgeons. HPB (Oxford). 2012;14(5):291-297. doi:10.1111/j.1477-2574.2012.00440.x
Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg. 2007;94(11):1386-1394. doi:10.1002/bjs.5836
Shindoh J, Truty MJ, Aloia TA, et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg. 2013;216(2):201-209. doi:10.1016/j.jamcollsurg.2012.10.018
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208-1215. doi:10.1016/S1470-2045(13)70447-9
Chen J, Li Q, Wang C, Zhu H, Shi Y, Zhao G. Simultaneous vs. staged resection for synchronous colorectal liver metastases: a metaanalysis. Int J Colorectal Dis. 2011;26(2):191-199. doi:10.1007/s00384-010-1018-2
Boudjema K, Locher C, Sabbagh C, et al. Simultaneous versus delayed resection for initially resectable synchronous colorectal cancer liver metastases: a prospective, open-label, randomized, controlled trial. Ann Surg. 2021;273(1):49-56. doi:10.1097/SLA.0000000000003848
Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23(36):9243-9249. doi:10.1200/JCO.2005.07.740
Wieser M, Sauerland S, Arnold D, Schmiegel W, Reinacher-Schick A. Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: a systematic review and meta-analysis of randomized trials. BMC Cancer. 2010;10(1):309. doi:10.1186/1471-2407-10-309
Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38-47. doi:10.1016/S1470-2045(09)70330-4
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi:10.1136/bmj.n160
Fitch Kb SJ, Aguilar MD, Bunand B, et al. The RAND/UCLA Appropriateness Method User’s Manual. Rand Corporation; 2001.
Vigano L, Pedicini V, Comito T, et al. Aggressive and multidisciplinary local approach to iterative recurrences of colorectal liver metastases. World J Surg. 2018;42(8):2651-2659. doi:10.1007/s00268-018-4525-x
Khan NA, Baerlocher MO, Owen RJ, et al. Ablative technologies in the management of patients with primary and secondary liver cancer: an overview. Can Assoc Radiol J. 2010;61(4):217-222. doi:10.1016/j.carj.2009.12.009
Schicho A, Niessen C, Haimerl M, et al. Long-term survival after percutaneous irreversible electroporation of inoperable colorectal liver metastases. Cancer Manag Res. 2019;11:317-322. doi:10.2147/CMAR.S182091
Hosein PJ, Echenique A, Loaiza-Bonilla A, et al. Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system. J Vasc Intervent Radiol. 2014;25(8):1233-1239. e2. doi:10.1016/j.jvir.2014.04.007
Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006;141(5):460-466. discussion 466-7. doi:10.1001/archsurg.141.5.460
Zhao Q, Cheng Z, Han Z, et al. Percutaneous microwave ablation versus open surgical resection for colorectal cancer liver metastasis. Front Oncol. 2021;11:638165. doi:10.3389/fonc.2021.638165
Shi Y, Wang Z, Chi J, et al. Long-term results of percutaneous microwave ablation for colorectal liver metastases. HPB (Oxford). 2021;23(1):37-45. doi:10.1016/j.hpb.2020.04.007
Kingham TP, Tanoue M, Eaton A, et al. Patterns of recurrence after ablation of colorectal cancer liver metastases. Ann Surg Oncol. 2012;19(3):834-841. doi:10.1245/s10434-011-2048-x
Ng KM, Chua TC, Saxena A, Zhao J, Chu F, Morris DL. Two decades of experience with hepatic cryotherapy for advanced colorectal metastases. Ann Surg Oncol. 2012;19(4):1276-1283. doi:10.1245/s10434-011-2025-4
Daye D, Hu EY, Glazer DI, Tuncali K, Levesque V, Shyn PB. Periprocedural factors associated with overall patient survival following percutaneous image-guided liver tumor cryoablation. Int J Hyperther. 2022;39(1):34-39. doi:10.1080/02656736.2021.2013552
Schuld J, Richter S, Kollmar O. The role of cryosurgery in the treatment of colorectal liver metastases: a matched-pair analysis of cryotherapy vs. liver resection. Hepato-Gastroenterology. 2014;61(129):192-196.
Puijk RS, Ruarus AH, Vroomen L, et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer. 2018;18(1):821. doi:10.1186/s12885-018-4716-8
Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017;109(9). doi:10.1093/jnci/djx015
Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005;23(7):1358-1364. doi:10.1200/JCO.2005.12.039
Tucci C, Trujillo M, Berjano E, Iasiello M, Andreozzi A, Vanoli GP. Pennes' bioheat equation vs. porous media approach in computer modeling of radiofrequency tumor ablation. Sci Rep. 2021;11(1):5272. doi:10.1038/s41598-021-84546-6
Vasiniotis Kamarinos N, Vakiani E, Gonen M, et al. Biopsy and margins optimize outcomes after thermal ablation of colorectal liver metastases. Cancers. 2022;14(3):14. doi:10.3390/cancers14030693
Kurilova I, Bendet A, Petre EN, et al. Factors associated with local tumor control and complications after thermal ablation of colorectal cancer liver metastases: a 15-year retrospective cohort study. Clin Colorectal Cancer. 2021;20(2):e82-e95. doi:10.1016/j.clcc.2020.09.005
van Duijnhoven FH, Jansen MC, Junggeburt JM, et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol. 2006;13(5):651-658. doi:10.1245/ASO.2006.08.014
Gavriilidis P, Roberts KJ, de'Angelis N, Aldrighetti L, Sutcliffe RP. Recurrence and survival following microwave, radiofrequency ablation, and hepatic resection of colorectal liver metastases: a systematic review and network meta-analysis. Hepatobiliary Pancreat Dis Int. 2021;20(4):307-314. doi:10.1016/j.hbpd.2021.05.004
Cirocchi R, Trastulli S, Boselli C, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2012(6):CD006317. doi:10.1002/14651858.CD006317.pub3
Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572-1578. doi:10.1200/JCO.2008.19.6329
Kobiela J, Spychalski P, Marvaso G, et al. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review. Crit Rev Oncol Hematol. 2018;129:91-101. doi:10.1016/j.critrevonc.2018.06.005
Jackson WC, Tao Y, Mendiratta-Lala M, et al. Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys. 2018;100(4):950-958. doi:10.1016/j.ijrobp.2017.12.014
Voglhuber T, Eitz KA, Oechsner M, Vogel MME, Combs SE. Analysis of using high-precision radiotherapy in the treatment of liver metastases regarding toxicity and survival. BMC Cancer. 2021;21(1):780. doi:10.1186/s12885-021-08488-y
Dawson LA, Winter KA, Katz AW, et al. NRG Oncology/RTOG 0438: a phase 1 trial of highly conformal radiation therapy for liver metastases. Pract Radiat Oncol. 2019;9(4):e386-e393. doi:10.1016/j.prro.2019.02.013
Goodman BD, Mannina EM, Althouse SK, Maluccio MA, Cardenes HR. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol. 2016;6(2):86-95. doi:10.1016/j.prro.2015.10.011
Sheikh S, Chen H, Sahgal A, et al. An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer. Radiother Oncol. 2022;167:187-194. doi:10.1016/j.radonc.2021.12.018
Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006;45(7):838-847. doi:10.1080/02841860600904821
Klement RJ, Guckenberger M, Alheid H, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease - influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017;123(2):227-233. doi:10.1016/j.radonc.2017.01.013
Mahadevan A, Blanck O, Lanciano R, et al. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch(R) Patient Registry. Radiat Oncol. 2018;13(1):26. doi:10.1186/s13014-018-0969-2
Rule W, Timmerman R, Tong L, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011;18(4):1081-1087. doi:10.1245/s10434-010-1405-5
Scorsetti M, Comito T, Clerici E, et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. Radiat Oncol. 2018;13(1):234. doi:10.1186/s13014-018-1185-9
Ahmed KA, Caudell JJ, El-Haddad G, et al. Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2016;95(5):1399-1404. doi:10.1016/j.ijrobp.2016.03.050
Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl l):S94-S100. doi:10.1016/j.ijrobp.2009.06.092
Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585-1591. doi:10.1200/JCO.2008.20.0600
Benson R, Madan R, Kilambi R, Chander S. Radiation induced liver disease: a clinical update. J Egypt Natl Cancer Inst. 2016;28(1):7-11. doi:10.1016/j.jnci.2015.08.001
Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53(4):810-821. doi:10.1016/s0360-3016(02)02846-8
Krishnan S, Lin EH, Gunn GB, et al. Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. Am J Clin Oncol. 2006;29(6):562-567. doi:10.1097/01.coc.0000236210.41199.91
He X, Zhang P, Li Z, et al. Curative-intent radiotherapy in patients with oligometastatic lesions from colorectal cancer: a single-center study. Medicine (Baltimore). 2018;97(40):e12601. doi:10.1097/MD.0000000000012601
Tai A, Erickson B, Li XA. Extrapolation of normal tissue complication probability for different fractionations in liver irradiation. Int J Radiat Oncol Biol Phys. 2009;74(1):283-289. doi:10.1016/j.ijrobp.2008.11.029
Kang JI, Sufficool DC, Hsueh CT, et al. A phase I trial of proton stereotactic body radiation therapy for liver metastases. J Gastrointest Oncol. 2019;10(1):112-117. doi:10.21037/jgo.2018.08.17
Hong TS, Wo JY, Borger DR, et al. Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype. J Natl Cancer Inst. 2017;109(9). doi:10.1093/jnci/djx031
Kim TH, Lee KS, Sim SH, et al. Clinical effectiveness of hypofractionated proton beam therapy for liver metastasis from breast cancer. Front Oncol. 2021;11:783327. doi:10.3389/fonc.2021.783327
Fukumitsu N, Okumura T, Numajiri H, et al. Follow-up study of liver metastasis from breast cancer treated by proton beam therapy. Mol Clin Oncol. 2017;7(1):56-60. doi:10.3892/mco.2017.1283
Fukumitsu N, Okumura T, Takizawa D, et al. Proton beam therapy for liver metastases from gastric cancer. J Radiat Res. 2017;58(3):357-362. doi:10.1093/jrr/rrw102
Coffman AR, Sufficool DC, Kang JI, et al. Proton stereotactic body radiation therapy for liver metastases-results of 5-year experience for 81 hepatic lesions. J Gastrointest Oncol. 2021;12(4):1753-1760. doi:10.21037/jgo-20-424
Shah RP, Brown KT, Sofocleous CT. Arterially directed therapies for hepatocellular carcinoma. AJR Am J Roentgenol. 2011;197(4):W590-W602. doi:10.2214/AJR.11.7554
Vogl TJ, Marko C, Langenbach MC, et al. Transarterial chemoembolization of colorectal cancer liver metastasis: improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial. Eur Radiol. 2021;31(4):2242-2251. doi:10.1007/s00330-020-07253-2
Nosher JL, Ahmed I, Patel AN, et al. Non-operative therapies for colorectal liver metastases. J Gastrointest Oncol. 2015;6(2):224-240. doi:10.3978/j.issn.2078-6891.2014.065
Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011;21(4):294-302. doi:10.1016/j.semradonc.2011.05.004
Artinyan A, Nelson R, Soriano P, et al. Treatment response to transcatheter arterial embolization and chemoembolization in primary and metastatic tumors of the liver. HPB (Oxford). 2008;10(6):396-404. doi:10.1080/13651820802356564
Touloupas C, Faron M, Hadoux J, et al. Long term efficacy and assessment of tumor response of transarterial chemoembolization in neuroendocrine liver metastases: a 15-year monocentric experience. Cancers. 2021;13(21):13. doi:10.3390/cancers13215366
Ngo L, Elnahla A, Attia AS, et al. Chemoembolization versus radioembolization for neuroendocrine liver metastases: a meta-analysis comparing clinical outcomes. Ann Surg Oncol. 2021;28(4):1950-1958. doi:10.1245/s10434-020-09469-4
Egger ME, Armstrong E, Martin RC, 2nd, et al. Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis. J Am Coll Surg. 2020;230(4):363-370. doi:10.1016/j.jamcollsurg.2019.12.026
Soulen Mw S, Garcia-Monaco R, Wileyto E, Avritscher R, El-Haddad G, El-Haddad G. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): first safety report. J Vasc Intervent Radiol. 2019;30(3 Suppl l):s49-s50. doi:10.1016/j.jvir.2018.12.151
Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009;115(9):1849-1858. doi:10.1002/cncr.24224
Mulcahy MF, Mahvash A, Pracht M, et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol. 2021;39(35):3897-3907. doi:10.1200/JCO.21.01839
Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247(6):1029-1035. doi:10.1097/SLA.0b013e3181728a45
Ridouani F, Soliman MM, England RW, et al. Relationship of radiation dose to efficacy of radioembolization of liver metastasis from breast cancer. Eur J Radiol. 2021;136:109539. doi:10.1016/j.ejrad.2021.109539
Fiorentini G, Sarti D, Nani R, Aliberti C, Fiorentini C, Guadagni S. Updates of colorectal cancer liver metastases therapy: review on DEBIRI. Hepat Oncol. 2020;7(1):HEP16. doi:10.2217/hep-2019-0010
Narsinh KH, Van Buskirk M, Kennedy AS, et al. Hepatopulmonary shunting: a prognostic indicator of survival in patients with metastatic colorectal adenocarcinoma treated with (90)Y radioembolization. Radiology. 2017;282(1):281-288. doi:10.1148/radiol.2016152100
Shimohira M, Sato Y, Yasumoto T, et al. Arterial embolization using microspheres for hypervascular liver metastases refractory to standard treatments: a multicenter prospective clinical trial. Cardiovasc Intervent Radiol. 2021;44(3):392-400. doi:10.1007/s00270-020-02673-5
Valsecchi ME, Terai M, Eschelman DJ, et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Intervent Radiol. 2015;26(4):523-532. e2. doi:10.1016/j.jvir.2014.11.037
Tanaka T, Nishiofuku H, Maeda S, et al. Repeated bland-TAE using small microspheres injected via an implantable port-catheter system for liver metastases: an initial experience. Cardiovasc Intervent Radiol. 2014;37(2):493-497. doi:10.1007/s00270-013-0691-2
Tai E, Kennedy S, Farrell A, Jaberi A, Kachura J, Beecroft R. Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis. Curr Oncol. 2020;27(6):e537-e546. doi:10.3747/co.27.6205
Nishiofuku H, Tanaka T, Matsuoka M, et al. Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: results of a phase I/II study. J Vasc Intervent Radiol. 2013;24(1):56-65. doi:10.1016/j.jvir.2012.09.010
Gruber-Rouh T, Naguib NN, Eichler K, et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int J Cancer. 2014;134(5):1225-1231. doi:10.1002/ijc.28443
Vogl TJ, Lahrsow M, Albrecht MH, Hammerstingl R, Thompson ZM, Gruber-Rouh T. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation. Eur J Radiol. 2018;102:138-145. doi:10.1016/j.ejrad.2018.03.015
Albert M, Kiefer MV, Sun W, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer. 2011;117(2):343-352. doi:10.1002/cncr.25387
Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011;18(1):192-198. doi:10.1245/s10434-010-1288-5
Aliberti C, Fiorentini G, Muzzio PC, et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead(R), drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res. 2011;31(12):4581-4587.
Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387-1395.
Fiorentini G, Sarti D, Nardella M, et al. Chemoembolization alone or associated with bevacizumab for therapy of colorectal cancer metastases: preliminary results of a randomized study. In Vivo. 2020;34(2):683-686. doi:10.21873/invivo.11824
Pernot S, Pellerin O, Artru P, et al. Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a phase 2 study. Br J Cancer. 2020;123(4):518-524. doi:10.1038/s41416-020-0917-4
Martin RC, 2nd, Scoggins CR, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649-3658. doi:10.1002/cncr.29534
Kennedy A, Cohn M, Coldwell DM, et al. Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. J Gastrointest Oncol. 2017;8(4):614-624. doi:10.21037/jgo.2017.03.10
Weiner AA, Gui B, Newman NB, et al. Predictors of survival after yttrium-90 radioembolization for colorectal cancer liver metastases. J Vasc Intervent Radiol. 2018;29(8):1094-1100. doi:10.1016/j.jvir.2018.02.020
Schindler P, Masthoff M, Harders F, et al. Efficacy of 90Y-radioembolization in metastatic colorectal cancer depending on the primary tumor side. Dig Dis. 2021;39(4):351-357. doi:10.1159/000512744
Wu V, Li MD, Goodwin JS, et al. Yttrium-90 hepatic radioembolization for advanced chemorefractory metastatic colorectal cancer: survival outcomes based on right- versus left-sided primary tumor location. AJR Am J Roentgenol. 2021;217(5):1141-1152. doi:10.2214/AJR.20.25315
Wong TY, Zhang KS, Gandhi RT, et al. Long-term outcomes following 90Y radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. BMC Cancer. 2022;22(1):224. doi:10.1186/s12885-022-09302-z
Schaarschmidt BM, Wildgruber M, Kloeckner R, et al. (90)Y radioembolization in the treatment of neuroendocrine neoplasms: results of an international multicenter retrospective study. J Nucl Med. 2022;63(5):679-685. doi:10.2967/jnumed.121.262561
Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159-1171. doi:10.1016/S1470-2045(17)30457-6
van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723-1731. doi:10.1200/JCO.2015.66.1181
Gibbs P, Heinemann V, Sharma NK, et al. Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies. Clin Colorectal Cancer. 2018;17(4):e617-e629. doi:10.1016/j.clcc.2018.06.001
Garlipp B, Gibbs P, Van Hazel GA, et al. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial. Br J Surg. 2019;106(13):1837-1846. doi:10.1002/bjs.11283
Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol. 2002;20(6):1499-1505. doi:10.1200/JCO.2002.20.6.1499
Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341(27):2039-2048. doi:10.1056/NEJM199912303412702
Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27(21):3465-3471. doi:10.1200/JCO.2008.20.1301
Levi FA, Boige V, Hebbar M, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2016;27(2):267-274. doi:10.1093/annonc/mdv548
Pak LM, Kemeny NE, Capanu M, et al. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: long term results and curative potential. J Surg Oncol. 2018;117(4):634-643. doi:10.1002/jso.24898
D'Angelica MI, Correa-Gallego C, Paty PB, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261(2):353-360. doi:10.1097/SLA.0000000000000614
Chan DL, Alzahrani NA, Morris DL, Chua TC. Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases. Surg Oncol. 2015;24(3):162-171. doi:10.1016/j.suronc.2015.06.014
Massani M, Bonariol L, Stecca T. Hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma, a comprehensive review. J Clin Med. 2021;10(12):10. doi:10.3390/jcm10122552
Cercek A, D'Angelica M, Power D, et al. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. Ann Surg Oncol. 2014;21(2):479-486. doi:10.1245/s10434-013-3275-0
Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24(9):1395-1403. doi:10.1200/JCO.2005.03.8166
Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40(2):150-160. doi:10.1200/JCO.21.00608
Holster JJ, El Hassnaoui M, Franssen S, et al. Hepatic arterial infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2022;29(9):5528-5538. doi:10.1245/s10434-022-11439-x
Tewes M, Peis MW, Bogner S, et al. Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: efficacy, safety and prognostic parameters. J Cancer Res Clin Oncol. 2017;143(10):2131-2141. doi:10.1007/s00432-017-2462-y
Engstrand J, Stromberg C, Nilsson H, Freedman J, Jonas E. Synchronous and metachronous liver metastases in patients with colorectal cancer-towards a clinically relevant definition. World J Surg Oncol. 2019;17(1):228. doi:10.1186/s12957-019-1771-9
Leibel SA, Pajak TF, Massullo V, et al. A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys. 1987;13(7):1057-1064. doi:10.1016/0360-3016(87)90045-9
Edyta WR, Jakub L, Jerzy W. Whole liver palliative radiotherapy for patients with massive liver metastases. Asian Pac J Cancer Prev. 2015;16(15):6381-6384. doi:10.7314/apjcp.2015.16.15.6381
Yeo SG, Kim DY, Kim TH, Kim SY, Hong YS, Jung KH. Whole-liver radiotherapy for end-stage colorectal cancer patients with massive liver metastases and advanced hepatic dysfunction. Radiat Oncol. 2010;5(1):97. doi:10.1186/1748-717X-5-97
Feng M, Smith DE, Normolle DP, et al. A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy. Int J Radiat Oncol Biol Phys. 2012;83(5):1441-1447. doi:10.1016/j.ijrobp.2011.10.020
Soliman H, Ringash J, Jiang H, et al. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J Clin Oncol. 2013;31(31):3980-3986. doi:10.1200/JCO.2013.49.9202
Ito K, Ogoshi Y, Shimizuguchi T. Palliative radiotherapy for multiple liver metastases: a retrospective analysis of 73 cases. Jpn J Clin Oncol. 2022;52(7):771-776. doi:10.1093/jjco/hyac050